A serum- and feeder-free system to generate CD4 and regulatory T cells from human iPSCs
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study presents a serum- and feeder-free method for large-scale production of induced pluripotent stem cell (iPSC)-derived CD4 T cells and regulatory T cells (Tregs). This scalable platform supports the development of cell therapies for oncology and autoimmune diseases.
Area Of Science
- Stem Cell Biology
- Immunology
- Cell Therapy
Background
- Induced pluripotent stem cells (iPSCs) offer a renewable source for cell manufacturing, overcoming primary cell limitations.
- Existing methods for clinical-grade iPSC-derived CD4 T cells and regulatory T cells (Tregs) often require animal components or complex organoid systems.
- Scalable production of iPSC-derived T cells is crucial for advancing cell-based therapies.
Purpose Of The Study
- To develop a serum- and feeder-free differentiation process for large-scale manufacturing of iPSC-derived CD4 T cells and Tregs.
- To demonstrate the efficient generation and functional characterization of iPSC-derived Tregs, including those engineered with a CAR.
- To establish a versatile iPSC platform for producing both CD4 T cells and Tregs for therapeutic applications.
Main Methods
- Optimized differentiation of iPSCs into CD4 T cells using specific concentrations of PMA/Ionomycin.
- Conversion of iPSC-derived CD4 T cells into Tregs using TGFβ and ATRA.
- Non-viral, targeted genetic engineering of iPSCs for CAR integration (e.g., HLA-A2 CAR).
- Phenotypic, transcriptional, and functional analysis of engineered iPSC-Tregs compared to primary Tregs.
Main Results
- High-efficiency generation of iPSC-derived CD4 T cells and subsequent conversion to Tregs.
- Successful non-viral, targeted integration of an HLA-A2 CAR into iPSCs.
- iPSC-Tregs (with or without CAR) demonstrated phenotypic, transcriptional, and functional similarity to primary Tregs.
- In vitro suppression of T-cell proliferation by iPSC-Tregs was confirmed.
Conclusions
- A scalable, serum- and feeder-free platform for manufacturing iPSC-derived CD4 T cells and Tregs has been established.
- This platform enables the production of functional iPSC-Tregs, suitable for Treg cell therapies.
- The technology complements existing iPSC-CD8 oncology products and offers a pathway for large-scale Treg cell therapy manufacturing.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
